SIZE XSSIZE SMSIZE MDSIZE LG

The following information helps you to find FDA Alerts and Pharmacist’s Applications to Practice quickly and easily. In cooperation with the Food and Drug Administration (FDA), and as a service to our members, HOPA periodically distributes information about newly approved therapies for cancer patients from FDA’s Office of Oncology Drug Products Director, Dr. Richard Pazdur to inform oncologists and professionals in oncology-related fields in a timely manner. Links to product labels will take you to relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, HOPA does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.

Along with HOPA’s Publications Committee, members also review new drug updates and provide analysis and research on the application of these new drugs or indications. Pharmacist’s Applications to Practice, or PAP, are listed after drugs that include the additional analysis. If you are interested in helping the Publications Committee with creating a Pharmacist's Application to Practice, please contact Jeff Price at jprice@hoparx.org.

You can also find additional information on FDA Alerts and Updates by listening to FDA Drug Safety Podcasts.

May 21, 2018

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf

On May 21, 2018, the Food and Drug Administration approved avatrombopag (Doptelet®, AkaRx Inc.) for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.

Approval was based on two international, identically designed, randomized, double-blind, placebo-controlled trials, ADAPT-1 and ADAPT-2. Patients (n=430) with chronic liver disease and thrombocytopenia received either avatrombopag (n=274) or placebo (n=156) daily for 5 days prior to a scheduled procedure, and had at least 1 post-dose safety assessment. Patients were randomized (2:1) to avatrombopag or placebo and stratified according to hepatocellular cancer status and bleeding risk associated with the elective procedure (low, moderate, or high).

Patients randomized to avatrombopag received differential dosing based on mean platelet count at entry. Patients with a baseline platelet count less than 40,000/L (low baseline platelet cohort) received avatrombopag 60 mg orally once daily for 5 consecutive days. Those with a baseline platelet count of 40,000 to less than 50,000/L (high baseline platelet cohort) received avatrombopag 40 mg orally once daily for 5 consecutive days. Eligible patients were scheduled to undergo their procedure 5 to 8 days after the last dose of study drug.

The primary efficacy endpoint was the proportion of patients, or responders, who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following an elective procedure.

In the low baseline platelet cohort, 66% and 69% of patients treated with avatrombopag responded in the ADAPT-1 and ADAPT-2 trials, respectively. For those receiving placebo, 23% (treatment difference 43%; 95% CI: 27, 58; p<0.0001) and 35% (treatment difference 34%; 95% CI: 16, 52; p=0.0006) responded in the ADAPT-1 and ADAPT-2 trials, respectively.

In the high baseline platelet cohort, 88% of avatrombopag-treated patients in both trials responded compared to 38% and 33% of placebo-treated patients. Treatment difference was 50% (95% CI: 32, 68; p<0.0001) in the ADAPT-1 trial and 55% (95% CI: 37, 73; p<0.0001) in the ADAPT-2 trial.

The most common adverse reactions reported in at least 3% of patients were pyrexia, abdominal pain, nausea, headache, fatigue, and peripheral edema.

The recommended dose of avatrombopag is based on a patient’s platelet count prior to a scheduled procedure. View the full Doptelet Prescribing Information for details.

FDA granted this application priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).

xs
sm
md
lg